Shuling Holloway
About Shuling Holloway
Shuling Holloway is the Executive Director and Global Cell Therapy Franchise Finance Lead at Bristol in New Jersey, United States. She has held various finance leadership roles at Bristol and has a strong background in finance and administration.
Company
Shuling Holloway is currently employed at Bristol as the Executive Director and Global Cell Therapy Franchise Finance Lead, based in New Jersey, United States. Bristol is renowned for its advanced pharmaceutical practices, specifically in the realm of cell therapy. Holloway's role involves managing the financial operations and strategies essential to the company's cell therapy division, reflecting her extensive experience in both finance and global operations.
Title
In her role as Executive Director and Global Cell Therapy Franchise Finance Lead, Shuling Holloway oversees the financial management of Bristol's cell therapy initiatives. Holloway's responsibilities include developing financial strategies, overseeing budgeting processes, and ensuring accurate financial forecasting to support the growth and sustainability of Bristol's cell therapy operations. Previously, she has held various significant roles within the company, showcasing her trajectory of progressive leadership positions.
Education and Expertise
Shuling Holloway holds an MBA in Accounting and Finance from Rutgers University - Graduate School Newark, completed between 1998 and 2000. Additionally, she earned a Master of Landscape Architecture from the University of Pennsylvania, completed from 1991 to 1994. Her diverse educational background lays a strong foundation for her expertise in financial strategy and operational management. Holloway's extensive experience in finance and her involvement in complex mergers and acquisitions underscore her technical proficiency and strategic acumen in her field.
Professional Background
Holloway has an extensive professional background primarily at Bristol. From 2017 to 2020, she served as Executive Director, Finance Transformation in Princeton, New Jersey. Before that, she was the Head of China Finance and Administration from 2014 to 2017 in Shanghai City, China. Her earlier roles include Director, Finance Operations (2012 to 2014) and Finance Director, Devens Operations (2007 to 2012). Holloway also worked at Mead Johnson Nutrition as Associate Director, Intercontinental Finance (2005 to 2007), and at Bristol-Myers Squibb as Plant Controller, Indiana Technical Operations (2004 to 2005). These positions have equipped her with a robust understanding of financial management across different geographies and operational scales.
Professional Achievements
Shuling Holloway has made notable contributions to Bristol's financial strategies. She led the finance integration during the acquisition of Celgene, developed a new forecasting model that improved accuracy by 15% for the Global Cell Therapy Franchise, and supported the expansion of cell therapy manufacturing capabilities. Holloway also played a pivotal role in the launch of Bristol's first CAR-T cell therapy product. She has participated in industry panels discussing the financial aspects of cell therapy commercialization and received the Bristol-Myers Squibb Finance Excellence Award for her exceptional contributions.